Endothelial-derived vasoactive mediators in polycystic kidney disease  by Al-Nimri, Muna A. et al.
Kidney International, Vol. 63 (2003), pp. 1776–1784
VASCULAR BIOLOGY–HEMODYNAMICS–HYPERTENSION
Endothelial-derived vasoactive mediators in polycystic
kidney disease
MUNA A. AL-NIMRI, RADKO KOMERS, TERRY T. OYAMA, AROHAN R. SUBRAMANYA,
JESSIE N. LINDSLEY, and SHARON ANDERSON
Division of Nephrology and Hypertension, Oregon Health and Science University, and Portland VA Medical Center, Portland, Oregon
Endothelial-derived vasoactive mediators in polycystic kidney An important factor which accelerates renal failure in
disease. ADPKD is hypertension, which occurs prior to loss of
Background. Autosomal dominant polycystic kidney disease renal function in 50% to 75% of patients with ADPKD
(ADPKD) is characterized by hypertension and renal vasocon-
[1, 2]. Angiographic analysis of polycystic kidneys revealsstriction. Mediators of these hemodynamic changes are not well
marked distortion of the renal vascular tree and cysticunderstood, but evidence suggests that endothelial-derived me-
compression of surrounding tissue, suggesting that vascu-diators may participate.
Methods. Baseline measurements of blood pressure, protein- lar attenuation and parenchymal ischemia may be con-
uria, and urinary nitrite/nitrate excretion were performed in con- tributing to the generation of hypertension and progres-
trol and cystic male Han:SPRD rats (6 weeks of age). They were sion of renal failure in this disorder [3]. Findings of low
then treated with the nitric oxide (NO), nitric oxide synthase renal plasma flow rates, high renal vascular resistance,(NOS) inhibitor, NG-nitro-L-arginine methyl ester (L-NAME),
and elevation of filtration fraction [4–8], as well as severeor vehicle, for 6 weeks. After repeat systemic measurements,
sclerosis of the preglomerular vessels even early in therenal function was determined using inulin and para-aminohip-
purate (PAH) clearances. Levels of renal endothelin-1 (ET-1) course of the disease [9], are further evidence for relative
and renal endothelial NOS (eNOS) proteins were determined, intrarenal vasoconstriction in patients with ADPKD.
and immunohistochemistry localized renal eNOS and neuronal Several vasoactive systems, including the renin-angio-
NOS (nNOS). tensin system (RAS) [10–12] and the sympathetic nervousResults. Administration of L-NAME aggravated systemic hy-
system [13–15], have been suggested to contribute to thepertension and renal vasoconstriction in the cystic rats, but did
observed vasoconstriction and pathogenesis of chronic re-not affect the progression of proteinuria or cystic expansion.
Cystic rats demonstrated marked increases in renal ET-1 and nal failure in ADPKD. Recent studies have further invoked
eNOS levels. L-NAME reduced eNOS expression in the mem- a role for alterations in the natural balance between endo-
brane compartment, but increased eNOS in the cytosol. Local- thelial-derived constricting and relaxing factors. Enhanced
ization studies indicated that renal eNOS was abundant in formation or activity of endothelin may play role. Innonvascular compartments, but not in renal vascular and glo-
support of this hypothesis, elevated systemic and/or renalmerular structures, whereas renal nNOS was diffusely dimin-
levels of endothelin have been noted clinically [16, 17]ished.
Conclusion. These alterations of endothelial-derived media- and experimentally [18, 19]. In addition, endothelium-
tors (up-regulation of ET-1, and dysfunction of the NO system) dependent relaxation is impaired in both experimental
contribute to vasoconstriction, and thereby are likely to con- [15] and clinical [20] ADPKD, in association with findings
tribute to the progressive loss of renal function in polycystic of decreased constitutive nitric oxide synthase (NOS) activ-kidney disease (PKD).
ity in resistance vessels [abstracts; Wang D et al, J Am
Soc Nephrol 11:400A, 2000; Wang D, J Am Soc Nephrol
400A; Wang D, Proc XVth Intl Cong Nephrol, 1999].Autosomal dominant polycystic kidney disease
In the current study, we examined the hypothesis that(ADPKD) is one of the most common hereditary dis-
an imbalance in endothelial-derived vasoactive mediators
eases, representing approximately 10% of the cases of (endothelin and NO) contributes to systemic and renal
end-stage renal disease (ESRD) in the United States. vasoconstriction, and cystic disease progression, in the
Han:SPRD model of polycystic kidney disease (PKD).
Key words: polycystic kidney, nitric oxide, endothelin, cystic disease,
glomerular filtration rate, proteinuria.
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provided by Dr. Benjamin Cowley, University of Kansas tion fraction (FF), and renal vascular resistance (RVR)
were determined using standard formulas.Medical Center, Kansas City, Kansas. Male heterozy-
gous cystic rats (Cy/) and unaffected littermate control
Morphologyrats (/) were studied. All rats were fed standard rat
chow (Rodent Laboratory Chow 5001, Purina Mills, After completion of hemodynamic studies, the right
kidney was removed, decapsulated, snap-frozen in liquidRichmond, IN, USA) ad libitum, and tap water, unless
otherwise specified. These studies were approved by the N2 and stored at –70C for Western blot analysis. The
left kidney was then excised and immersed in 10% forma-Portland Veterans Affairs Institutional Animal Care and
Use Subcommittee. lin. The fixed kidneys were dehydrated through a graded
series of ethanols, embedded in paraffin, sectioned atAt 6 weeks of age, all rats underwent serial measure-
ments of awake systolic blood pressure by the tail-cuff 4 m thickness, and placed onto glass slides. Renal mor-
phometry was assessed quantitatively using the pointmethod, and 24-hour urine collections for measurements
of urinary protein excretion (UprotV) and nitrite nitrate counting method. Kidney paraffin sections were stained
with hematoxylin and eosin. Subcapsular fields were as-(UNOxV). Thereafter, they were subdivided to receive
either the NOS inhibitor, NG-nitro-l-arginine methyl- sessed using a rigid protocol for random positioning.
Kidneys were assessed at low power (100) to avoidester (L-NAME) (Sigma Chemical Co., St. Louis, MO,
USA), 20 to 35 mg/L in the drinking water, or tap water, sampling variations produced by massive cystic dilation.
To assess cyst burden, random fields (10 per rat) werefor 6 weeks. Thereafter (at 12 weeks of age), systolic
blood pressure measurements and urinary collections assayed for percentage of area comprised of cysts.
were repeated to assess changes from baseline. After
Immunohistochemistrythe systemic measurements, the rats underwent renal
function studies as described below. At the end of the Kidney sections were deparaffinized in xylene, rehy-
drated through graded ethanols to water, and pretreatedexperiment, the right kidney was snap-frozen in liquid
N2 and stored at 80C for subsequent measurement of by steaming in 10% antigen retrieval buffer (BioGenex
Laboratories, San Ramon, CA, USA). After treatmentendothelin-1 (ET-1) level, and for Western blot experi-
ments. The left kidney was placed in formalin, and subse- with protein-blocking solution, the slides were incubated
overnight at 4C with primary mouse anti-endothelialquently processed for morphology and immunohisto-
chemistry. NOS (eNOS), anti-neuronal NOS (nNOS) antibodies, or
anti-inducible NOS (iNOS) (diluted 1:200, Transduction,
Renal function studies Lexington, KY, USA) or with the same concentration of
nonimmune mouse immunoglobulin G (IgG) as a control.Rats were anesthetized with inactin (100 mg/kg intra-
peritoneally) and placed on a thermoregulated table. Endogenous peroxidase activity was blocked with 3% H2O2
solution in methanol. The primary antibody was local-The left femoral artery was cannulated and a baseline
sample of blood was collected for determination of he- ized using the Vectastain ABC-Elite peroxidase detec-
tion system (Vector Laboratories, Burlingame, CA, USA).matocrit, inulin, and para-aminohippurate (PAH) blanks.
This arterial catheter was used for subsequent blood This was followed by reaction with diaminobenzidine as
chromogen and counterstaining with hematoxylin (Sigmasampling and for estimation of mean arterial pressure
(MAP) via an electronic transducer connected to a direct Chemical Co.). Sections of each polycystic kidney were
processed in parallel with appropriate control tissue.writing recorder. After tracheostomy, bilateral internal
jugular catheters were inserted for infusions of rat serum,
Immunoblottingand 10% inulin (Cypros, Carlsbad, CA, USA) with 0.8%
PAH (Merck, West Point, PA, USA) in 0.9% NaCl (1.2 Kidneys were finely minced and then disrupted in
a motor-driven tissue homogenizer in 10 mmol/L Tris,mL/hour). To adjust for reduced renal function, cystic
rats were given 6% inulin with 0.6% PAH in saline. The 1 mmol/L ethylenediaminetetraacetic acid (EDTA), 20
g/mL leupeptin, 20 g/mL benzamidine, and 40 g/mLleft ureter was catheterized for urine collections. To main-
tain euvolemia, rat serum was infused at 0.1 mL/min for phenylmethylsulfonyl fluoride (PMSF). Homogenates
were centrifuged at 500 g for 15 minutes at 4C, anda total equal to 1% of the body weight, followed by a
reduction in infusion rate to 0.42 mL/hour, to maintain the resulting nuclei-free supernatant was centrifuged at
100,000 g for 60 minutes at 4C. The total protein contenta constant hematocrit. After equilibration, duplicate or
triplicate 20-minute urine collections with mid-point of resulting pellets and supernatants representing mem-
brane and cytosolic fractions was equalized by dilutionblood collections were made, for measurement of inulin
and PAH clearances. Blood was obtained simultaneously in sodium dodecyl sulfate-polyacrylmide gel electropho-
resis (SDS-PAGE) sample buffer and incubated for 5for measurement of hematocrit, inulin, and PAH. Glo-
merular filtration rate (GFR) by inulin clearance, effec- minutes at 97C. Denatured proteins (60 g for pellets,
80 g for supernatant) were then separated throughtive renal plasma flow (ERPF), by PAH clearance, filtra-
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Fig. 2. Urinary protein excretion (UprotV) before (6 weeks) and afterFig. 1. Systolic blood pressure (SBP) before (6 weeks) and after (12 (12 weeks) L-NAME. *P  0.05 vs. control; †P  0.05 vs. C/L-NAME;
weeks) L-NAME. *P  0.05 vs. control; †P  0.05 vs. C/L-NAME; ‡P  0.05 vs. cystic; #P  0.05 vs. 6 weeks in same group.
‡P  0.05 vs. cystic; #P  0.05 vs. 6 weeks in same group.
Analytic methodsSDS-PAGE (8%) and transferred to polyvinylidine di-
For calculation of GFR, inulin concentrations in plasmafluoride (PVDF) membranes (Bio-Rad Laboratories,
Inc., Hercules, CA, USA). Membranes were extensively and urine were determined by the macro-anthrone
washed with Tris-buffered saline (TBS-T) (10 mmol/L method. RPF was determined by PAH clearance, using
Tris, 150 mmol/L NaCl, 0.05% Tween-20) and then colorimetric methodology. ET-1 was measured by en-
blocked overnight with TBS-T containing 5% nonfat dry zyme immunoassay (Cayman Chemical, Ann Arbor, MI,
milk. After blocking, membranes were again extensively USA). Urinary NOx was determined by the Greiss method
washed with TBS-T and incubated overnight with the using a commercial kit (Cayman Chemical). Urinary to-
above mentioned anti-eNOS primary antibody diluted tal protein content was measured by precipitation with
1:800 in TBS-T containing 3% milk. Immunodetection 3% sulfosalicylic acid (Sigma Chemical Co.).
was accomplished by incubating membranes with a goat
anti-mouse IgG secondary antibody conjugated with Statistics
horseradish peroxidase (HRP) for 45 minutes (1:100,000; Values are reported as means SEM. Statistical anal-
Pierce Chemical Co., Rockford, IL, USA) in TBS-T con- ysis was performed by analysis of variance followed by
taining 5% nonfat dry milk. Visualization was performed computation of modified t values according to the method
with an enhanced chemiluminescence (ECL) Western of Bonferroni (for multiple groups), as appropriate. Val-
blotting kit (Supersignal West Dura; Pierce Chemical
ues that were not normally distributed were analyzed
Co.) according to the manufacturer’s instructions. Resul-
by nonparametric methods. Statistical significance was
tant films (Eastman Kodak Co., Scientific Imaging Sys-
defined as P  0.05.tems, New Haven, CT) were scanned using a flatbed
scanner and images analyzed with NIH Image software
with the gel-plotting macro. To control for equal protein RESULTS
loading, the membranes were then stripped in stripping
Body weights did not differ among groups, nor didbuffer (Chemicon International, Temecula, CA, USA)
weight gain over the period of study. Results of systemicfor 30 minutes at room temperature, blocked for 30 min-
and whole kidney measurements are depicted in Figuresutes in a blocking buffer provided by the manufacturer,
1 to 4. Initial values for systolic blood pressure were gener-and reincubated for 1 hour at room temperature with
ally comparable, although slightly higher in cystic rats thangoat antiactin antibody (Santa Cruz Biotechnology Inc.,
in the control rats which later received L-NAME (Fig. 1).Santa Cruz, CA, USA), followed by a 45-minute incuba-
In control rats, L-NAME increased blood pressure some-tion with antigoat IgG secondary antibody (Ab) conju-
what, whereas the increment was much more pronouncedgated with HRP (1:4000; Amersham Pharmacia Biotech,
in cystic rats. Values for UprotV were within the normalPiscataway, NJ, USA), and the reaction was visualized
range in all groups at the start of the study, althoughwith ECL as described above. Since conventional West-
slightly lower in cystic rats than in the control rats whichern blot technique does not allow separate analysis of
later received L-NAME (Fig. 2). Proteinuria did not riseeNOS dimer and monomer expression (further discussed
in any control group, but rose substantially in cystic rats,below), expression of the eNOS dimer was also deter-
with or without L-NAME, during the treatment period.mined in kidney samples, after separation through SDS-
PAGE (8%) at 4 to 7C without prior heat denaturation. UNOxV was comparable in all groups at baseline, and not
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Fig. 4. Renal endothelin-1 (ET-1) in control and cystic rats. *P  0.05
vs. control; †P  0.05 vs. C/NAME; ‡P  0.05 vs. cystic.
Fig. 3. Urinary nitrite  nitrate excretion (UNOxV) before (6 weeks)
and after (12 weeks) L-NAME. *P  0.05 vs. control; †P  0.05 vs. C/
L-NAME; ‡P  0.05 vs. cystic; #P  0.05 vs. 6 weeks in same group.
kidneys, as another possible marker of renal eNOS dys-
function and reduced NO bioavailability in this model.
Expression of the eNOS dimer was proportional to the
affected with this dose of L-NAME in control rats (Fig. 3), overall expression of the enzyme in both cystic and non-
whereas UNOxV was markedly suppressed by L-NAME cystic rats, and did not appear to be altered in the cystic
in cystic rats (Fig. 3). kidneys (not shown).
Results of renal hemodynamic and structural studies Immunohistochemical studies provided localization
are summarized in Table 1. Body weights did not differ information. Unlike the control rats (Fig. 6 A and C),
among groups. Kidney weights, and kidney/body weight immunoreactive eNOS expression was barely detectable
ratios, were markedly elevated in the cystic groups, and in the vasculature and glomeruli of cystic rats (Fig. 6 B
not affected by L-NAME. Values for MAP were some- and D). In control rats, diffuse eNOS staining was also
what elevated with L-NAME in control rats, but much apparent in tubules, particularly in the medulla (not
more so in cystic rats. As in prior studies [21, 22], cystic shown). In the cystic rats, immunoreactive eNOS was
rats exhibited profound renal vasoconstriction, with re- abundant in the walls of some cysts with preserved epi-
duced values for GFR and ERPF, as compared with thelial layers. Regarding nNOS, noncystic control rats
controls. In control rats, L-NAME did not significantly demonstrated the typical pattern, with cortical expres-
change values for GFR, ERPF, FF, or RVR. However, sion localized in macula densa cells (Fig. 7A). In contrast,
in the cystic rats, L-NAME was associated with further glomeruli with adjacent nNOS-positive macula densa
reductions in GFR and ERPF, and significant increases cells were virtually absent in cystic kidneys. This was in
in FF and RVR. Thus, as compared with the control rats, part due to decreased numbers of glomeruli with struc-
the cystic rats exhibited enhanced systemic and renal turally sound adjacent macula densa. However, even in
vascular responsiveness to L-NAME. Morphologically, well-preserved macula densa, immunoreactive nNOS was
NOS inhibition had no effect on renal enlargement, or scarcely detectable (Fig. 7B). Occasional clusters of
on cyst burden, in the cystic rats (Table 1). nNOS positive tubular cells were present in locations
Renal ET-1 levels were strikingly elevated in cystic without an apparent association with any juxtaglomeru-
rats, as compared with control rats (Fig. 4). NOS inhibi- lar apparatus (JGA) or glomeruli (Fig. 7C). In addition
tion did not affect renal ET-1 levels in control rats, but to constitutive NOS isoforms, we studied iNOS immuno-
significantly lowered ET-1 levels in the cystic rats, al- reactivity in control and cystic kidneys. However, this
though levels still remained much higher than in noncys- protein was below the limit of detection in these kidneys
tic control rats. (not shown).
Further studies evaluated renal constitutive NOS ex-
pression with a particular emphasis on eNOS (NOS3).
DISCUSSIONRenal protein expression of total eNOS was significantly
increased in both membrane-bound (Fig. 5A) and cyto- The pathogenesis of progressive cyst expansion and
solic (Fig. 5B) fractions of kidneys from cystic rats, as loss of renal function in ADPKD involves several mecha-
compared with noncystic controls (P  0.01). As com- nistic pathways. Hemodynamic factors have been impli-
pared with untreated cystic rats, L-NAME treatment cated, in that parenchymal ischemia is believed to con-
led to a decrease in the membrane-associated eNOS tribute to sclerosis and fibrosis. In the baseline state,
fraction, but an increase in the level of cytosolic eNOS, the cystic rats in the present study exhibited marked
consistent with displacement of the enzyme from mem- vasoconstriction. This observation is in accord with our
brane to the cytosol. Additional analyses determined prior studies in this model [21, 22], as well as with studies
in human ADPKD patients [5–8]. The mechanisms un-expression of the eNOS dimer in cystic and noncystic
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Table 1. Renal hemodynamic and structural effects of L-NAME
Control Control/L-NAME Cystic Cystic/L-NAME
(N  10) (N  8) (N  10) (N  8)
Body weight g 36110 3689 3599 34612
Left kidney weight g 1.470.06 1.760.10 4.010.13a,b 4.020.10a,b
Left kidney weight/100 g body weight 0.410.01 0.480.02 1.110.03a,b 1.170.05a,b
Mean arterial pressure mm Hg 1124 1417a 1243a 18116a,b,c
Glomerular filtration rate mL/min 1.670.14 1.660.12 0.870.04a,b 0.440.09a,b,c
Effective renal plasma flow rate mL/min 6.000.73 5.370.25 3.370.27a,b 1.280.32a,b,c
Filtration fraction 0.300.04 0.310.01 0.270.02 0.360.02c
Renal vascular resistance mm Hg/mL/min 12.52.2 13.43.1 24.81.5 147.348.9a,b,c
Cyst burden % — — 36.61.3 30.82.2
a P  0.05 vs. control; b P  0.05 vs. control/L-NAME; c P  0.05, cystic vs. cystic/L-NAME
in regulation of blood pressure and renal function has
been clearly shown in recent years; NOS inhibition in-
duces striking increases in blood pressure and decre-
ments in renal function even in normal animals [23–25].
Increased dependence on endogenous NO has been noted
in a number of renal disease models, including diabetes
[26, 27], normal aging [28, 29], and renal ablation [30].
In PKD, the hemodynamic abnormalities of the cystic
kidney suggest that alterations in endogenous vasoactive
mediators are likely to play an important role, but the
role of NO is just beginning to be explored. Most of the
available evidence comes from extrarenal systems. In
normotensive patients with ADPKD, Wang, Iversen, and
Strandgaard [20] found impaired relaxation to acetylcho-
line in small peripheral resistance vessels, with failure
to improve after l-arginine or to worsen after L-NAME.
Experimentally, the same group has reported impaired
endothelium-dependent relaxation in mesenteric arter-
ies isolated from polycystic kidney rats [15]. Yoshida,
Bengal, and Torres [31] reported on the gender-depen-
dent effects of L-NAME in the Han:SPRD model. When
given in doses much larger than those used in the present
study, L-NAME increased blood pressure and plasma
urea and creatinine levels (though not cyst burden or
kidney weight) in male rats, while effects were much
attenuated in female rats.
The present study confirms the enhanced systemic and
renal hemodynamic sensitivity to NOS inhibition in cys-
tic rats. To our knowledge, ours is the first study to deter-
mine the renal responses to NOS inhibition in this model
using formal clearance methods. We show here that the
impairment in GFR in cystic rats given L-NAME results
Fig. 5. Representative Western blots of endothelial nitric oxide synthase from intense hypoperfusion. The increases in FF and RVR(eNOS) in control and cystic rats, and cystic rats treated with L-NAME.
are consistent with profound effects of systemic NOS(A) Membrane-bound eNOS. (B) Cytosolic eNOS. *P 0.01 vs. control;
†P  0.05 vs. cystic/L-NAME; ‡P  0.05 vs. cystic. inhibition with pressor doses of l-arginine analogues on
intrarenal arteriolar resistances, as has been previously
found with NOS inhibition in normal animals [23, 24].
derlying this intense vasoconstriction are not yet fully The present findings are in general accord with prior
explained. studies of the renal content and distributions of NOS
To address this issue we investigated the two major isoforms in PKD. In kidneys from ADPKD patients,
endothelial vasoactive systems in cystic kidneys, using a brief report noted some staining for iNOS in cystic
epithelium, but to a significantly lesser degree than wasboth functional and tissue approaches. The role of NO
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Fig. 6. Immunolocalization of eNOS protein
(arrows). Immunoreactive eNOS was fully ex-
pressed in renal arterioles and glomeruli of
noncystic control rats (A, C ), but undetectable
in vascular structures of cystic rats (B, D).
Fig. 7. Immunohistochemistry depicting distri-
bution of nNOS (arrows). Control rats demon-
strated typical distribution of nNOS in MD cells
(A). In contrast, nNOS immunoreactivity was
scarce in MD cells of cystic rats (B). Cystic
rats demonstrated occasional ectopic clusters of
nNOS-positive tubular cells (C). Non-immune
serum controls showed no staining (D).
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seen in acquired cystic disease associated with renal cell By heat-denaturing the samples before electrophoresis,
conventional Western blot technique does not allow sep-carcinoma [32]. Wang and Strandgaard [abstract; Wang
D et al, J Am Soc Nephrol 11:400A, 2000] noted de- arate analysis of eNOS dimer and monomer expression.
Considering the lower NOx excretion, and overall renalcreased constitutive NOS activity in kidney tissues and
mesenteric arteries in rats at 7 weeks of age. In another vasoconstriction, which is further accentuated by NOS
inhibition, it is conceivable that although more abundantpreliminary report, this group found decreasing expres-
sion of iNOS and nNOS, but no change in eNOS, in the in the cystic rats, renal eNOS is present predominantly in
the monomeric form. However, our observation that theprogression of cyst formation [abstract; Wang D, Proc
XVth Intl Congr Nephrol, 1999]. The authors concluded dimer expression was proportional to the overall expres-
sion of the enzyme (no change in the dimer:monomerthat down-regulation of iNOS and nNOS may contribute
to cyst pathogenesis. More recently, genotyping of pa- ratio in cystic kidneys) does not support the hypothesis
of a defective functional status of eNOS in cystic rats.tients with ADPKD found a link between polymor-
phisms of the ENOS gene, which encodes eNOS, and Further insight into this issue has been provided by im-
munohistochemical studies. The increase in renal eNOSseverity of disease in ADPKD [33]. In that study, the
Glu298ASP allele was associated with shorter renal sur- was apparently attributable to abundant expression in
nonvascular compartments, particularly in the devel-vival, and decreased renal arterial eNOS protein (but
not mRNA) expression, in male patients with ADPKD. oping cysts. In this compartment, eNOS might contribute
to cyst pathogenesis, but would not be expected to influ-Our findings are in agreement with the clinical observa-
tion of decreased vascular eNOS expression in PKD. ence the vascular hemodynamic changes.
In addition to the alterations in eNOS expression,The present study further analyzed eNOS renal pro-
tein expression and renal immunolocalization of both con- changes in nNOS could also contribute to renal vasocon-
striction in cystic rats. Both isoforms have been citedstitutive NOS isoforms. Regarding eNOS, we found a clear
increase in both the membrane-bound and cytosolic frac- as relevant to hemodynamic regulation. In the case of
experimental diabetes, nNOS is an important mediatortions from whole cystic kidneys. At first glance, our studies
focusing on the renal activity and expression of NOS pro- of renal hemodynamic function [36, 37]. As shown by
the immunohistochemical studies, nNOS in cystic kid-duced potentially contradictory data. A marked increase
in renal eNOS protein expression in cystic rats was asso- neys was either absent or isolated from the vascular
compartment. In the case of PKD, the relative functionalciated with lower RPF and UNOxV, and yet, the renal hemo-
dynamic response to NOS inhibition was enhanced in the roles of NOS isoforms are as yet unknown, as all studies
published thus far have been performed using nonspe-cystic rats. Recent progress in understanding the biochem-
istry of eNOS provides a potential explanation for these cific NOS blockers such as L-NAME. Studies using iso-
form-specific blockers will be needed to dissect the rela-discrepancies. Localization of eNOS to the plasma mem-
brane is essential for agonist-stimulated NO release, and tive functional roles of the various NOS isoforms in PKD.
In contrast to the obvious hemodynamic effects, NOSinterventions that induce translocation of eNOS from
the plasma membrane markedly attenuate acetylcholine- inhibition had no effect on the progression of structural
renal injury, as assessed by measurements of proteinuria,induced eNOS activation [34]. The paradox between the
baseline renal hemodynamics and markedly increased re- kidney weight, or cyst burden. This finding is consistent
with that of Yoshida, Bengal, and Torres [31], in thatnal expression of eNOS in cystic rats suggests alterations
in the functional status of eNOS and/or expression of the those authors also found no significant effect of NOS
inhibition on acceleration of structural injury. It is possi-enzyme in hemodynamically irrelevant localizations in the
cystic kidney. Abundance of the enzyme in cytosolic frac- ble that despite its role in hemodynamic regulation, the
NO system plays a less important role in the pathogenesistions of the cystic kidneys may indicate a defect in mem-
brane targeting of the enzyme, and consequent reduced of structural injury in this model. Alternatively, it is con-
ceivable that we might have seen a more dramatic effectbioavailability of NO for hemodynamic actions. In this
context, it is of note that treatment with L-NAME resulted of L-NAME had the intervention been started earlier,
before the disease had progressed so far.in a further increase in the cytosolic eNOS fraction in
the cystic kidneys, while the membrane-bound fraction ET-1 may play a role, as well. Plasma ET-1 levels are
high in patients with ADPKD [16, 17], and ET-1 is pres-was markedly reduced. However, considering the abun-
dance of eNOS in membrane-bound fractions, there should ent in human cyst fluid [16]. In the cpk mouse model,
ET and ET receptor mRNAs increase in parallel withbe still a sufficient amount of the functioning enzyme to
synthesize NO for vasoactive purposes. Therefore, we cyst growth [18]. The results of the present study confirm
a prior report [19] that renal ET-1 levels are elevatedfurther determined the expression of the eNOS dimer
in membrane-bound fractions as one of the possible mark- in the Han:SPRD model. In that study, acute ETA/ETB
receptor antagonism reduced MAP and increased ERPF,ers of eNOS functional integrity. eNOS can be viewed
as a dual enzyme producing NO in a dimeric state [35]. suggesting a significant functional role for this hormone.
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We found that L-NAME reduced renal ET-1 levels in renal RAS is activated in this model [11, 12]. We have
reported that in contrast to the very low PRC values,cystic rats, but did not normalize them. Whether this
renal angiotensin II levels are only slightly reduced, andincomplete reduction in renal ET-1 level was sufficient
that renal responses to blockade of the RAS with enala-to have any impact on the renal vasoconstriction cannot
prilat are exaggerated in cystic rats [21]. With respect tobe ascertained from our data, but it was clearly not suffi-
our present findings, hemodynamic actions of angioten-cient to counteract the vasoconstrictive influence of NOS
sin II may be exaggerated due to lack of buffering byblockade. Effects on cystic progression are also difficult
dysfunctional NO system, which normally antagonizesto ascertain, though one could speculate that partial sup-
the actions of angiotensin II in the kidney. Furthermore,pression of ET-1 contributed to the fact that the NOS
angiotensin II actions may be enhanced by concomitantinhibitor did not aggravate structural injury (see below).
activation of the ET system. Thus, relative activation ofEffects of ET-1 in the normal rat kidney are complex.
the intrarenal RAS may be one factor contributing toHercule and Oyekan [38] have reported contrasting ef-
vasoconstriction in this model.fects of ET-1 on cortical and medullary flow. In the cortex
Taken together, our results suggest the following sce-the peptide acts as a vasoconstrictor via ETA/ETB recep-
nario. The polycystic kidney exhibits normal intrarenaltors, whereas in the medulla, ET-1 acts as vasodilator.
RAS activity, which is inappropriately high in the contextThe latter action is mediated by ETB receptor signaling
of the systemic hypertension and suppression of the sys-via NO. Furthermore, as suggested by studies in geneti-
temic RAS. Endothelin is clearly activated in the poly-cally modified mice with a dysfunctional ETB receptor,
cystic kidney, and likely to participate in impairment ofthis molecule may play an important role in sodium ex-
renal perfusion and hemodynamic function, as well ascretion, in particular during high salt intake [39]. Thus,
progression of cyst formation. The NO system displaysin addition to a possible role in cyst formation, increased
complex alterations; it is suppressed in the vascular com-renal ET-1 may represent a compensatory mechanism
partment and up-regulated in ectopic locations, leavingaimed at preservation of medullary blood flow progres-
the kidney less able to compensate for the vasoconstric-sively limited by expanding cysts, and at maintaining
tive influences, and also more sensitive to NOS inhibition.sodium balance as GFR decreases. ET-1 actions via the
Impaired compensatory dilation, physiologically pro-ETB receptor may also contribute to paradoxic findings
vided by NO, leads to relatively unopposed vasoconstric-of enhanced renal expression of eNOS and enhanced
tion, and marked renal hypoperfusion and hypofiltration.responsiveness to NOS inhibition in cystic rats.
The resultant renal ischemia contributes to tubulointer-ET-1 and NO systems have complex interactions. One
stitial injury, and further loss of renal function.of the major new findings in the present study is that
Treatment of hypertension in ADPKD may attenuateNOS inhibition with L-NAME markedly decreased renal
the hemodynamic influences, and evidence suggests thatET-1 content in cystic, but not in normal, kidneys. This
drugs that counteract the intrarenal vasoconstriction maysuggests that ET-1 synthesis in the cystic kidney is stimu-
be of particular benefit. Angiotensin-converting enzymelated by NO. There is no clear explanation for this obser-
(ACE) inhibition effectively counteracts the renal vaso-vation and we cannot exclude that this phenomenon is
constriction in experimental PKD [21], and recent reportsrelatively unique for the cystic kidney. Previous data in
have challenged the previous notion that ACE inhibitorsvarious experimental settings indicate that NOS inhibi-
are not protective in patients with ADPKD [42] [ab-tion is associated with an increase, rather than decrease,
stract; Jafar TH, J Am Soc Nephrol 11:392A, 2000]. Fur-in ET-1 levels [40]. On the other hand, parallel up-regula-
ther studies, both experimental and clinical, are neededtion of both systems has been described, for example,
to determine the most effective renoprotective strategywith administration of insulin in the human forearm cir-
for patients at risk.culation [41], and we have noted a similar relationship
between L-NAME and renal ET-1 in experimental dia-
CONCLUSIONbetes [abstract; Oyama T, J Am Soc Nephrol 9:638A,
1998]. Considering the functional balance between the Control and cystic rats were treated with the NOS
two systems, it is possible that inhibition of one system inhibitor L-NAME, or vehicle, for 6 weeks. Administra-
causes down-regulation of the other. tion of L-NAME aggravated systemic hypertension and
Previous studies suggested additional mechanisms that renal vasoconstriction in the cystic rats, but did not affect
may explain PKD-associated renal vasoconstriction. For the progression of proteinuria or cyst expansion. Cystic
example, renal parenchymal ischemia, resulting from com- rats exhibited marked increases in renal ET-1 and eNOS
pression induced by massive cystic enlargement, has been levels, but diminished expression of eNOS in renal vascu-
postulated to play a role, perhaps by stimulating the RAS. lar and glomerular structures, and diffusely diminished
In this regard, plasma renin concentration (PRC) is ele- renal nNOS expression. This imbalance of endothelial-
vated in some patients with PKD [10], but values for derived mediators has the net effect to promote vasocon-
PRC in the Han:SPRD cystic rats are low [21, 22]. Never- striction, which likely contributes to progressive loss of
renal function in PKD.theless, there are several lines of evidence that the intra-
Al-Nimri et al: Endothelial factors in PKD1784
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